SPL 2.11% 9.3¢ starpharma holdings limited

ASCO Presentations 2024, page-23

  1. 1,797 Posts.
    lightbulb Created with Sketch. 322
    “…to present the results from the phase I/II study…”

    Not “intermediate results”, just “results”

    Looks like the Irinotecan trial has finally been concluded (even though treatment may still be ongoing). Let’s see what the quarterly report has to say later today or tomorrow.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.